To address these issues, IL15c‐expressing or ALT‐803‐loaded chimeric antigen receptor (CAR)‐modified T or NK cells have been explored.[8] While significantly improving the tolerance of IL15‐based therapy, these strategies heavily rely on the specificity of CAR‐T and CAR‐NK cells and commonly suffer from on‐target off‐tumor adverse effects.[9] Therefore, novel IL15 supplementary therapies are still of urgent need. The gene discussed is IL15; the disease is neoplasm.